Dr Reddy's Laboratories, which has received approval from the Indian drug regulator for restricted emergency use of COVID-19 vaccine Sputnik V, today said it expects the first lot of stock from Russian Direct Investment Fund by May end.

In September 2020, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the rights for distribution of the first 100 million doses in India. Later, it was enhanced to 125 million.